Bora Pharmaceuticals Adds Roller Compaction Capabilities
April 7, 2021
Roller compaction technology will add additional solid dose processing capabilities to the site and to Bora’s contract services offerings. “The successful installation of this roller compactor demonstrates that Bora Pharmaceuticals is committed to meeting the changing needs of our clients and their products,” said Tom Chang, President, Bora Pharmaceutical Laboratories. “The investment is testament to our dedication to providing the highest quality products and ensuring we have the flexibility and capabilities to support our clients for years to come .”
In addition to successfully completing US FDA Inspections, the Zhunan site has successfully completed CGMP inspections by the MHRA and the TFDA and is TAA Compliant. The Zhunan facility is one of Bora’s three state-of-the-art contract manufacturing (CMO) sites and manufactures products for the North American and European markets. The company also recently announced that it had successfully completed the acquisition of GSK’s Mississauga, Ontario (Canada) facility. The site represents Bora Pharmaceuticals’ first manufacturing facility in North America and will become home to its headquarters in the region.
For more information about Bora’s services, please visit: www.boracorpcdmo.com
About Bora Pharmaceuticals:
Employing over 900 people, the publicly listed (6472.TWO) Bora Pharmaceuticals is a premier international CGMP CDMO specializing in complex oral solid dose (tablet & capsules), liquids (solutions, suspensions, & nasal sprays), and semisolid (creams & gels) pharmaceutical products for Clinical through Commercial manufacturing and packaging. Bora owns and operates three state-of the-art CGMP manufacturing facilities (Taiwan and Canada) built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. Our TAA-compliant sites deliver to more than 100 markets around the world including the USA, Canada, EU, Southeast Asia, Middle East, and South and Central Americas. DocuSign Envelope ID: DCB08C8C-931F-44FF-BDC7-
For further information please visit www.boracorpcdmo.com
For media enquiries:
Lara Lovenbury PR Manager, ramarketing, lara@ramarketingpr.com, +44(0)7732 681275
Lonnie Barish Vice President, Business Development and Marketing 1866-6PHARMA, Lonnie.barish@bora-corp.com